Together, we are creating a path toward better drug development. Faster. Cheaper. More productive. So that the world can live to its full potential.
We know that statement is somewhat audacious. It should be. But we believe it’s possible and that’s why we started GenoFAB. To build a better R&D process by designing and deploying better biofoundries. We are scientists, consultants, engineers, biologists, teachers, students, business strategists, logicians, and dreamers. Pioneers envisioning a better way. We came together to solve the problems that keep drug innovation divided. To put productivity first and make it fast by breaking down the walls that hinder progress. Because discovery leaves too much to chance, GenoFAB is changing the future through solutions to better drug development.
Engineers transforming the production of research data
Dr. Peccoud is a synthetic biology pioneer who quickly understood the potential of a model-driven approach to the development of biotechnology products.
Dr. Peccoud founded GenoFAB to support the synthetic biology programs of biotech companies and research organizations who need to accelerate the development of revolutionary products used to save lives, feed the world, and support sustainable economic growth.
Today, Dr. Peccoud is the Abell Chair in Synthetic Biology in the Department of Chemical and Biological Engineering at Colorado State University (CSU). He leads the Colorado Cyberbiofoundry, a high-throughput facility to accelerate the development of new viral vectors and other gene delivery systems for biomedical applications.
He is the founding Editor-in-Chief of the journal Synthetic Biology published by Oxford University Press. Dr. Peccoud is on the editorial boards for Trends in Biotechnology and Nucleic Acids Research and has published more than 100 articles with more than 4,000 citations.
Since 2008, Dr. Peccoud has advised the U.S. Department of Defense, Department of Justice, and members of the intelligence community to help them anticipate and manage cyberbiosecurity threats emerging at the interface between the biological space and cyberspace. He is a member of the Engineering Biology Research Consortium Council and Security Working Group. Looking forward, Dr. Peccoud is creating an indelible imprint with GenoFAB by proposing a new R&D paradigm at the intersection of science and engineering.
With experience in research and business, Ms. Miller possesses a distinctive skillset oriented towards nurturing collaboration and creating growth opportunities for scientists and investors. In a prior role within the Multifamily Real Estate sector, she was overseeing a portfolio with an approximate value of $700 million. In this capacity, she directly engaged with institutional partners and operators to enhance wealth generation through meticulously optimized and managed processes.
A molecular biologist by training, Ms. Miller started her career contributing to several vaccine development projects. This hands-on experience gives her a unique perspective on the challenges faced by life scientists responsible for the development of new biologic drugs.
More recently, Ms. Miller combined her scientific and business expertise to the lead the development of proposals to research programs funded various government agencies such as the National Institutes of Health or the National Science Foundation.
In this context, she has been instrumental in the development of an integrated and diversified portfolio of intellectual properties that includes patents, copyrights, trade secrets, and trademarks. In this role, she has been involved or led efforts to identify opportunities to create new IP assets, license existing assets, and prosecute IP rights infringements.
Ms. Miller is an active member of the scientific and business community. She is a member of the Engineering Biology Research Consortium (EBRC), where she focuses on Policy, International Engagement, and Security.
Looking forward, Ms. Miller focuses her readily adaptable set of scientific and business skills to deliver efficient, reproducible outcomes rooted in finely tuned and engineered research workflows. Augmented by exceptional interpersonal aptitudes, she eagerly anticipates contributing to the advancement of fellow colleagues and clients in their pursuit of scientific progress and the development of life saving drugs.